Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Bevacizumab and Erlotinib in Combination With Docetaxel and Prednisone for Patients With Hormone Refractory Prostate Cancer

NCT00996502 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT00996502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00996502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Bevacizumab and Erlotinib in Combination With Docetaxel and Prednisone for Patients With Hormone Refractory Prostate Cancer
Lead sponsor
Columbia University
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2006
Completion date
March 31, 2010
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer